Production (Stage)
PMV Pharmaceuticals, Inc.
PMVP
$0.95
$0.022.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.12M | 11.40M | 4.94M | 5.54M | 5.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.56M | 25.17M | 21.89M | 20.17M | 17.62M |
| Operating Income | -21.56M | -25.17M | -21.89M | -20.17M | -17.62M |
| Income Before Tax | -19.63M | -23.00M | -19.15M | -17.39M | -15.27M |
| Income Tax Expenses | -2.20M | 0.00 | 74.00K | -16.17M | -- |
| Earnings from Continuing Operations | -17.44M | -23.00M | -19.23M | -1.21M | -15.27M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.44M | -23.00M | -19.23M | -1.21M | -15.27M |
| EBIT | -21.56M | -25.17M | -21.89M | -20.17M | -17.62M |
| EBITDA | -21.53M | -25.13M | -21.52M | -19.80M | -17.26M |
| EPS Basic | -0.34 | -0.44 | -0.37 | -0.02 | -0.30 |
| Normalized Basic EPS | -0.24 | -0.28 | -0.23 | -0.21 | -0.18 |
| EPS Diluted | -0.34 | -0.44 | -0.37 | -0.02 | -0.30 |
| Normalized Diluted EPS | -0.24 | -0.28 | -0.23 | -0.21 | -0.18 |
| Average Basic Shares Outstanding | 51.95M | 51.82M | 51.57M | 51.48M | 51.45M |
| Average Diluted Shares Outstanding | 51.95M | 51.82M | 51.57M | 51.48M | 51.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |